168 related articles for article (PubMed ID: 33992790)
1. Patients' safety skills assessment with biologics and JAK inhibitors: Update of the BioSecure questionnaire.
Beauvais C; Gaud-Listrat V; Sellam J; Fayet F; Béranger M; Deparis N; Antignac M; Sordet C; Rodère M; Gossec L
Joint Bone Spine; 2021 Oct; 88(5):105215. PubMed ID: 33992790
[No Abstract] [Full Text] [Related]
2. [Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Best practice with JAK inhibitors.].
Yamaoka K
Clin Calcium; 2018; 28(5):678-685. PubMed ID: 29731464
[TBL] [Abstract][Full Text] [Related]
3. [Drug therapy of rheumatoid arthritis: where do biologics and novel synthetic disease-modifying antirheumatic drugs stand today?].
Kaudewitz D; Lorenz HM
Inn Med (Heidelb); 2023 Oct; 64(10):1005-1012. PubMed ID: 37493758
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis.
Kang EH; Liao KP; Kim SC
Curr Rheumatol Rep; 2018 May; 20(7):42. PubMed ID: 29846814
[TBL] [Abstract][Full Text] [Related]
5. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.
Smolen JS; Landewé RBM; Bijlsma JWJ; Burmester GR; Dougados M; Kerschbaumer A; McInnes IB; Sepriano A; van Vollenhoven RF; de Wit M; Aletaha D; Aringer M; Askling J; Balsa A; Boers M; den Broeder AA; Buch MH; Buttgereit F; Caporali R; Cardiel MH; De Cock D; Codreanu C; Cutolo M; Edwards CJ; van Eijk-Hustings Y; Emery P; Finckh A; Gossec L; Gottenberg JE; Hetland ML; Huizinga TWJ; Koloumas M; Li Z; Mariette X; Müller-Ladner U; Mysler EF; da Silva JAP; Poór G; Pope JE; Rubbert-Roth A; Ruyssen-Witrand A; Saag KG; Strangfeld A; Takeuchi T; Voshaar M; Westhovens R; van der Heijde D
Ann Rheum Dis; 2020 Jun; 79(6):685-699. PubMed ID: 31969328
[TBL] [Abstract][Full Text] [Related]
6. HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
Gremese E; Gasbarrini A; Ferraccioli G
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32098858
[No Abstract] [Full Text] [Related]
7. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.
Decarriere G; Barnetche T; Combe B; Gaujoux-Viala C; Lukas C; Morel J; Daien C
Arthritis Care Res (Hoboken); 2021 Jun; 73(6):873-884. PubMed ID: 32216091
[TBL] [Abstract][Full Text] [Related]
8. JAK Inhibitors: What Is New?
Reddy V; Cohen S
Curr Rheumatol Rep; 2020 Jul; 22(9):50. PubMed ID: 32700001
[TBL] [Abstract][Full Text] [Related]
9. Which should be first: biologic DMARDs or Janus kinase inhibitors?
Koike T
Rheumatology (Oxford); 2023 May; 62(5):1738-1739. PubMed ID: 36355459
[No Abstract] [Full Text] [Related]
10. Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.
Meyer A; Wittekind PS; Kotschenreuther K; Schiller J; von Tresckow J; Haak TH; Kofler DM
Ann Rheum Dis; 2021 Dec; 80(12):e196. PubMed ID: 31744827
[No Abstract] [Full Text] [Related]
11. Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer
Rosenzwajg M; Lorenzon R; Klatzmann D
Ann Rheum Dis; 2021 Dec; 80(12):e197. PubMed ID: 31964656
[No Abstract] [Full Text] [Related]
12. Recent progress in treatments of rheumatoid arthritis: an overview of developments in biologics and small molecules, and remaining unmet needs.
Tanaka Y
Rheumatology (Oxford); 2021 Dec; 60(Suppl 6):vi12-vi20. PubMed ID: 34951925
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Jegatheeswaran J; Turk M; Pope JE
Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
[TBL] [Abstract][Full Text] [Related]
14. Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome.
Tanaka Y
Expert Opin Pharmacother; 2023; 24(16):1791-1798. PubMed ID: 37563102
[TBL] [Abstract][Full Text] [Related]
15. Drugs for rheumatoid arthritis.
Med Lett Drugs Ther; 2018 Jul; 60(1552):123-128. PubMed ID: 30044766
[No Abstract] [Full Text] [Related]
16. Expanded table: some biologic agents and JAK inhibitors for RA.
Med Lett Drugs Ther; 2018 Jul; 60(1552):e130-e134. PubMed ID: 30044768
[No Abstract] [Full Text] [Related]
17. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
18. [JAK inhibitors in rheumatology].
Cantagrel A
Rev Prat; 2022 Nov; 72(9):935-940. PubMed ID: 36512005
[No Abstract] [Full Text] [Related]
19. The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?
Tanaka Y
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i1-i3. PubMed ID: 30806705
[No Abstract] [Full Text] [Related]
20. Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.
Winthrop KL; Citera G; Gold D; Henrohn D; Connell CA; Shapiro AB; Shi H; Onofrei AM; Pappas DA; Schulze-Koops H
Ann Rheum Dis; 2021 Jan; 80(1):134-136. PubMed ID: 33046447
[No Abstract] [Full Text] [Related]
[Next] [New Search]
